SLS Stock Summary and Trading Ideas (Sellas Life Sciences Group | NASDAQ:SLS)

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sellas Life Sciences Group trades on the NASDAQ stock market under the symbol SLS.

As of April 11, 2025, SLS stock price climbed to $1.13 with 446,880 million shares trading.

SLS has a beta of 0.38, meaning it tends to be less sensitive to market movements. SLS has a correlation of 0.01 to the broad based SPY ETF.

SLS has a market cap of $102.66 million. This is considered a Micro Cap stock.

In the last 3 years, SLS traded as high as $5.58 and as low as $.50.

The top ETF exchange traded funds that SLS belongs to (by Net Assets): VTI, VXF, IWC.

SLS has underperformed the market in the last year with a return of -19.3%, while SPY returned +4.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SLS shares. However, SLS has outperformed the market in the last 3 month and 2 week periods, returning +18.6% and +1.8%, while SPY returned -7.7% and -3.9%, respectively. This indicates SLS has been having a stronger performance recently.

SLS support price is $1.06 and resistance is $1.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLS shares will trade within this expected range on the day.